M&A / Deals Zydus to acquire Assertio in $166m deal Pharmaceutical TechnologyZydus Lifesciences is set to acquire all outstanding Assertio common shares in a $166.4m deal, via its subsidiary Zydus Worldwide DMCC.Read full story pharminent May 14, 2026 (Last updated: May 14, 2026) Pharmaceutical Technology Zydus Lifesciences is set to acquire all outstanding Assertio common shares in a $166.4m deal, via its subsidiary Zydus Worldwide DMCC. Read full story Post navigation Previous: Pfizer receives EC approval for Hympavzi to treat haemophiliaNext: ECO 2026: gut hormone signals differ in T1D with obesity Related Stories M&A / Deals Solstice Oncology secures $225m to drive porustobart’s development for cancer pharminent September 10, 2026 M&A / Deals UK’s Claret Capital raises 575m for European biotechs pharminent September 7, 2026 M&A / Deals GSK wagers up to $1.3B on a different kind of cancer drug pharminent September 3, 2026